Harish V. Pai
YOU?
Author Swipe
View article: Author Correction: Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study
Author Correction: Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study Open
View article: Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study
Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study Open
Sequence variants (SV) in protein bio therapeutics can be categorized as unwanted impurities and may raise serious concerns in efficacy and safety of the product. Early detection of specific sequence modifications, that can result in alter…
View article: Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine
Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine Open
Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years. Insulin glargine has a relatively constant concentration-time profile that …
View article: Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab Open
[This corrects the article DOI: 10.1371/journal.pone.0180088.].
View article: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab Open
CD6 is associated with T-cell modulation and is implicated in several autoimmune diseases. We previously demonstrated that Itolizumab, a CD6 domain 1 (CD6D1) specific humanized monoclonal antibody, inhibited the proliferation and cytokine …